Alto Neuroscience (NYSE:ANRO) Stock Falls 7.2% – Should You Sell?

Posted by Brenda Bartman on Oct 15th, 2026

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) shares fell 7.2% during trading on Tuesday. The company traded as low as $22.40 and last traded at $22.4160. Approximately 367,786 shares changed hands during mid-day trading, a decline of 10% from the average daily volume of 408,330 shares. The stock had previously closed at $24.15.

Wall Street Analysts Forecast Growth

ANRO has been the topic of several research reports. Wedbush boosted their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. BTIG Research raised their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. HC Wainwright lifted their price objective on shares of Alto Neuroscience from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.25.

Read Our Latest Analysis on ANRO

Alto Neuroscience Trading Up 4.9%

The company’s fifty day moving average is $30.42 and its 200-day moving average is $26.28. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $893.30 million, a P/E ratio of -9.40 and a beta of 1.31.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08. As a group, sell-side analysts anticipate that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Nicholas Smith sold 24,056 shares of Alto Neuroscience stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total transaction of $621,125.92. Following the sale, the chief financial officer directly owned 24,060 shares in the company, valued at approximately $621,229.20. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 11.25% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds have recently made changes to their positions in the company. Quantinno Capital Management LP boosted its holdings in shares of Alto Neuroscience by 1.4% in the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after buying an additional 490 shares during the period. Farther Finance Advisors LLC increased its position in shares of Alto Neuroscience by 48,581.8% during the third quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock worth $137,000 after acquiring an additional 5,344 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Alto Neuroscience by 6.3% during the first quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock worth $2,327,000 after acquiring an additional 6,100 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Alto Neuroscience by 26.1% during the first quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock worth $884,000 after acquiring an additional 8,148 shares during the period. Finally, GK Wealth Management LLC acquired a new stake in shares of Alto Neuroscience during the second quarter worth $226,000.

Alto Neuroscience Company Profile

(Get Free Report)

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and neurological disorders. The company seeks to use neuroscience, digital health tools and biological and behavioral biomarkers to identify patient subgroups that may respond to specific treatments.

Alto’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions. Its development programs are designed to address limitations of conventional psychiatric treatment by matching therapies to patient characteristics and measuring treatment response through objective data.